I'm LongbridgeAI, I can summarize articles.HC Wainwright & Co. maintained their Buy rating on Enliven Therapeutics's stock with a price target of $73.00.
The price target implies an upside of 95.6% from the Oct 16 close of $37.32.
Key takeaways from the analyst note
Positive Trial Outlook: Enliven Therapeutics is expected to initiate the ENABLE-2 trial, which has been deemed relatively de-risked due to alignment with the FDA on its design. The high probability of positive outcomes stems from encouraging results in previous trials for their product candidate ELVN-001, specifically targeting chronic myeloid leukemia.
Strong Comparative Efficacy: The preliminary data from the Phase 1 ENABLE trial demonstrate that relcobatinib (ELVN-001) achieved major molecular response rates that significantly outperformed existing treatments like bosutinib and asciminib. This positions Enliven's candidate as a potentially more effective option for patients, enhancing investor confidence in the company's future.
Explore more price target data and ratings for Enliven Therapeutics on the .
